Edition:
United States

AnaptysBio Inc (ANAB.OQ)

ANAB.OQ on NASDAQ Stock Exchange Global Select Market

71.69USD
3:59pm EST
Change (% chg)

$0.88 (+1.24%)
Prev Close
$70.81
Open
$70.83
Day's High
$72.82
Day's Low
$70.52
Volume
51,569
Avg. Vol
140,314
52-wk High
$134.00
52-wk Low
$62.90

Latest Key Developments (Source: Significant Developments)

Anaptysbio Announces Third Quarter 2018 Financial Results
Thursday, 8 Nov 2018 04:15pm EST 

Nov 8 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES.ANAPTYSBIO INC QTRLY LOSS PER SHARE $0.66.ANAPTYSBIO INC QTRLY COLLABORATION REVENUE WAS $5.0 MILLION FOR 3 MONTHS ENDED SEPT 30, 201 COMPARED TO NO REVENUE FOR 3 MONTHS ENDED SEPT 30, 2017.ANAPTYSBIO INC - EXPECTS THAT CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND CURRENT OPERATING PLAN AT LEAST THROUGH END OF 2020.ANAPTYSBIO INC - ANTICIPATES TOP-LINE DATA FROM ECLIPSE TRIAL WILL BE AVAILABLE IN H2 OF 2019.  Full Article

AnaptysBio Reports Qtrly Loss Per Share $0.57
Tuesday, 7 Aug 2018 06:30am EDT 

Aug 7 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES.ANAPTYSBIO INC QTRLY LOSS PER SHARE $0.57.ANAPTYSBIO - EXPECTS CASH, CASH EQUIVALENTS & INVESTMENTS TO FUND CURRENT OPERATING PLAN THROUGH END OF 2019.ANAPTYSBIO - CASH, CASH EQUIVALENTS & INVESTMENTS TOTALED $300.6 MILLION AS OF JUNE 30, 2018 VERSUS $324.3 MILLION AS OF DEC 31, 2017.  Full Article

AnaptysBio Qtrly ‍Loss Per Share $0.30
Monday, 5 Mar 2018 04:15pm EST 

March 5 (Reuters) - AnaptysBio Inc ::ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND 2018 PIPELINE MILESTONES.Q4 REVENUE $3.0 MILLION.QTRLY ‍LOSS PER SHARE $0.30.‍EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2019​.  Full Article

Anaptysbio qtrly loss per share $0.45‍​
Tuesday, 7 Nov 2017 06:00am EST 

Nov 7 (Reuters) - Anaptysbio Inc ::Anaptysbio announces third quarter 2017 financial results and provides pipeline updates.Qtrly loss per share $0.45‍​.Q3 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results
Monday, 6 Nov 2017 04:15pm EST 

Nov 6 (Reuters) - Anaptysbio Inc :Anaptysbio reports positive anb019 top-line phase 1 clinical trial results.Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties in study​.ANB019 was well-tolerated by all subjects and no dose-limiting toxicities were observed to date in study​.Plans to initiate phase 2 clinical trials of ANB019 in generalized pustular psoriasis, palmo-plantar pustular psoriasis patients in 2018​.  Full Article

Cormorant Asset Management reports 5.02 pct passive stake in Anaptysbio as of Oct. 19 ‍​
Friday, 20 Oct 2017 04:28pm EDT 

Oct 20 (Reuters) - Cormorant Asset Management LLC: :Cormorant Asset Management, LLC reports 5.02 percent passive stake in Anaptysbio Inc as of October 19 - SEC filing ‍​.  Full Article

AnaptysBio prices public offering of 3 mln shares at $68.50 per share
Thursday, 12 Oct 2017 07:18pm EDT 

Oct 12 (Reuters) - AnaptysBio Inc -:AnaptysBio announces pricing of public offering.Says public offering of 3.00 million common shares priced at $68.50per share.  Full Article

Anaptysbio files for offering of 3 million shares
Tuesday, 10 Oct 2017 04:21pm EDT 

Oct 10 (Reuters) - Anaptysbio Inc :Anaptysbio files for offering of 3 million shares for up to $121.1 million – sec filing .  Full Article

AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis
Tuesday, 10 Oct 2017 06:30am EDT 

Oct 10 (Reuters) - AnaptysBio Inc : :AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis.AnaptysBio Inc - ‍83 percent of patients achieved EASI-50 at day 29 following a single dose of ANB020​.AnaptysBio Inc - ‍ANB020 was generally well tolerated in all patients as of this interim analysis​.AnaptysBio-Continues to advance its ongoing ANB020 phase 2A studies in adults with severe peanut allergy with topline data expected in Q4 of 2017​.Anaptysbio Inc - ‍during first half of 2018, co plans to initiate a phase 2B randomized, double-blinded, placebo-controlled study​.AnaptysBio Inc - no severe adverse events have been reported to date on ‍ANB020 ​.AnaptysBio- also continues to advance ongoing ANB020 phase 2A studies in adults with severe eosinophilic asthma, topline data expected in first half of 2018​.  Full Article

‍adage Capital reports a 6.05 percent passive stake in AnaptysBio
Monday, 2 Oct 2017 05:22pm EDT 

Oct 2 (Reuters) - Adage Capital Partners LP:‍Adage Capital Partners GP reports a 6.05 percent passive stake in AnaptysBio Inc​ as of September 22 - SEC filing​.  Full Article